BBK Worldwide, patient recruitment leader and clinical research and development consultancy, announces the opening of a West Coast office in Los Angeles. This expansion is a response to increasing demands from biotechnology/biopharmaceutical research sponsors for worldwide coverage to successfully meet recruitment deadlines. Building on the 2009 office opening of BBK Worldwide – Osaka in Japan, and adding to BBK’s existing global alliance network and Boston, London, and Prague locations, the Los Angeles office creates an opportunity for BBK to better serve clients in the Pacific time zone.
According to BBK Founding Principal Joan F. Bachenheimer, “Our West Coast clients operate in a hotbed of biopharmaceutical innovation. BBK’s on-site consultation better ensures their trials are primed for success with early recruitment strategies, technology, training, and tactical implementation support.”
On assignment from BBK’s global mobilization team, project and marketing experts will staff and augment the West Coast workforce, as needed, to respond directly to client and campaign needs. “Putting ‘feet on the street’ via a West Coast office means that we can better partner with clinical team leads as well as provide immediate, and if necessary, on-site enrollment coaching and training to study coordinators and site staff,” Bachenheimer added.
BBK Director of Strategic Development Andrew N. Sacher, Esq. commented, “We are finding with our presence in Osaka that real-time BBK availability in a region focused on biopharmaceutical innovation empowers clients to invest in the most advanced patient recruitment techniques. By opening the West Coast office, we anticipate spurring similar interest and commitment to enhancing clinical trial enrollment – particularly as the sheer number of biopharmaceutical studies being conducted continues to rise.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.